Overview

 


IBI is focused on developing a broad portfolio of clinically superior proprietary products, based on its Verisome® drug delivery technology. The company’s initial focus is on its pipeline of reduced-risk, low-cost development programs targeting every major ophthalmic market.  IBI’s lead portfolio product, IBI-10090, is currently in late stage clinical trials. A New Drug Application (NDA) is planned for late 2015.

 

Share
Icon Bioscience, Inc. | 1253 Reamwood Ave. | Sunnyvale, CA | 94089 | 650-369-4049
Copyright © 2014 Icon Bioscience, Inc. · Optimization by MME ·